Psychiatry Research: Neuroimaging
Volume 183, Issue 2 , Pages 151-156 , 30 August 2010

Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [11C]verapamil as a probe for P-glycoprotein function

  • Onno L. de Klerk

      Affiliations

    • Department of Psychiatry, University Medical Center Groningen (UMCG), P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • Psychiatric Hospital GGZ Drenthe, P.O. Box 30007, 9400 RA Assen, The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, University Medical Center Groningen (UMCG), P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel.: +31 50 3612056; fax +31 50 3619132.
    • ,
  • Antoon T.M. Willemsen

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, UMCG, Groningen, The Netherlands
    • ,
  • Fokko J. Bosker

      Affiliations

    • Department of Psychiatry, University Medical Center Groningen (UMCG), P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Anna L. Bartels

      Affiliations

    • Department of Neurology, UMCG, Groningen, The Netherlands
    • ,
  • N. Harry Hendrikse

      Affiliations

    • Department of Nuclear Medicine and PET Research, VU Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Johan A. den Boer

      Affiliations

    • Department of Psychiatry, University Medical Center Groningen (UMCG), P.O. Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Rudy A. Dierckx

      Affiliations

    • Department of Nuclear Medicine and Molecular Imaging, UMCG, Groningen, The Netherlands

Received 26 July 2009 ,Revised 7 February 2010 ,Accepted 6 May 2010.

References 

  1. Abrahim A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraia E, et al. Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35:116–123
  2. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research. 2008;42:884–893
  3. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology. 1999;39:361–398
  4. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Molecular Psychiatry. 2000;5:150–158
  5. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. Journal of Neural Transmission. 2008;115:1001–1009
  6. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Experimental Biology and Medicine (Maywood.). 2005;230:118–127
  7. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Molecular Pharmacology. 2007;71:667–675
  8. Di NF, Mercer SJ, Knight LA, Gabriel FG, Whitehouse A, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer. 2005;5:78
  9. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, Behavior, and Immunity. 2006;20:532–545
  10. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Therapeutic Drug Monitoring. 2004;26:180–185
  11. Eisel UL. Cytokines in degenerative brain diseases: lessons from transgenic animals. Current Topics in Microbiology and Immunology. 2002;265:49–62
  12. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates. The Journal of Pharmacy and Pharmacology. 2004;56:967–975
  13. Elsinga H, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Current Pharmaceutical Design. 2004;10:1493–1503
  14. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. Journal of Pharmacy & Pharmaceutical Sciences. 2004;7:359–371
  15. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. Journal of Neuroscience. 2002;22:RC216
  16. Gilmore JH, Jarskog LF, Vadlamudi S, Lauder JM. Prenatal infection and risk for schizophrenia: IL-Iß, IL-6 and TNFα inhibit cortical neuron dendrite development. Neuropsychopharmacology. 2004;29:1221–1229
  17. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Medical Genetics. 2005;6:7
  18. Harrison BJ, Yucel M, Shaw M, Brewer WJ, Nathan J, Strother SC, et al. Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naive schizophreniform psychosis. Psychiatry Research. 2006;148:23–31
  19. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Molecular Pharmacology. 2006;69:462–470
  20. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Research. 1999;59:2411–2416
  21. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. The American Journal of Psychiatry. 2005;162:2233–2245
  22. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. Journal of Cerebral Blood Flow and Metabolism. 2002;22:1271–1281
  23. Johnson WW. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods & Findings in Experimental & Clinical Pharmacology. 2002;24:501–514
  24. Kastelic, M., Koprivsek, J., Plesnicar, B.K., Serretti, A., Mandelli, L., Locatelli, I., Grabnar, I., Dolzan, V., 2010. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 34 (2), 387--392.
  25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  26. Kirschbaum KM, Henken S, Hiemke C, Schmitt U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behavioural Brain Research. 2008;188:298–303
  27. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology. 2005;57:176–179
  28. Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H. The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Research. 2008;160:308–315
  29. Lin YC, Ellingrod L, Bishop JR, Miller DS. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Therapeutic Drug Monitoring. 2006;28:668–672
  30. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nuclear Medicine and Biology. 2000;27:661–670
  31. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology & Therapeutics. 1997;62:248–260
  32. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, et al. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. Journal of Cerebral Blood Flow and Metabolism. 2007;27:424–433
  33. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 2001;21:778–796
  34. Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. The American Journal of Psychiatry. 1999;156:634–636
  35. Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin. 2005;31:672–696
  36. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. The Journal of Pharmacology and Experimental Therapeutics. 2000;293:376–382
  37. Pechandova K, Buzkova H, Slanar O, Perlik F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biologica (Praha). 2006;52:184–189
  38. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opinion on Drug Metabolism & Toxicologyl. 2008;4:1245–1264
  39. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain, Behavior, and Immunity. 2001;15:319–339
  40. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Current Topics in Medicinal Chemistry. 2004;4:1385–1398
  41. Sasongko L, Lin JM, Muzi M, Mankoff DA, Yang X, Collier AC, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology & Therapeutics. 2005;77:503–514
  42. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491–502
  43. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. The Journal of Clinical Investigation. 1996;97:2517–2524
  44. Selemon LD. Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease. Schizophrenia Bulletin. 2001;27:349–377
  45. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry. 1998;59(Suppl 20):22–33
  46. Shinkai T, De, L., V , Utsunomiya K, Sakata S, Inoue Y, Fukunaka Y, et al. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Medicine. 2008;10:362–367
  47. Stolp HB, Dziegielewska KM. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathology and Applied Neurobiology. 2009;35:132–146
  48. Tan KH, Purcell WM, Heales SJ, McLeod JD, Hurst RD. Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. NeuroReport. 2002;13:2593–2597
  49. Tan EK, Drozdzik M, Bialecka M, Honczarenko K, Klodowska-Duda G, Teo YY, et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neuroscience Letters. 2004;372:240–244
  50. Uhr M, Grauer MT, Yassouridis A, Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. Journal of Psychiatric Research. 2007;41:179–188
  51. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. The International Journal of Neuropsychopharmacology. 2004;7:415–419
  52. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006;187:415–423
  53. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006;187:415–423
  54. Weber CC, Kressmann S, Ott M, Fricker G, Muller WE. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry. 2005;38:293–300
  55. Wegman TD, Maas B, Elsinga H, Vaalburg W. An improved method for the preparation of [11C]verapamil. Applied Radiation and Isotopes. 2002;57:505–507
  56. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Current Drug Metabolism. 2004;5:11–19
  57. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006;7:987–993
  58. Yasui-Furukori N, Mihara K, Takahata T, Suzuki A, Nakagami T, De R, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Britisch Journal of Clinical Pharmacology. 2004;57:569–575
  59. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Progress in Neuropsychopharmacology & Biological Psychiatry. 2006;30:286–291
  60. Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sato Y, Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Progress in Neuropsychopharmacology & Biological Psychiatry. 2007;31:1230–1234
  61. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 2007;32:757–764

PII: S0925-4927(10)00158-7

doi: 10.1016/j.pscychresns.2010.05.002

Psychiatry Research: Neuroimaging
Volume 183, Issue 2 , Pages 151-156 , 30 August 2010

Article Tools

* Image Usage & Resolution